(PODD) Insulet - NASDAQ
Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 9.941m USD | Total Return: -52.6% in 12m
Avg Turnover: 225M
EPS Trend: 90.5%
Qual. Beats: 1
Rev. Trend: 99.8%
Qual. Beats: 16
Warnings
Below Avwap Earnings
Tailwinds
Garp
Insulet Corporation, headquartered in Acton, Massachusetts, develops and manufactures tubeless insulin delivery systems for people with insulin-dependent diabetes, primarily through its flagship Omnipod platform, which includes the Omnipod 5 automated insulin delivery system, the Omnipod DASH system, and the legacy Omnipod Insulin Management System. The Omnipod platform distinguishes itself from traditional tubed insulin pumps with its wearable, disposable pod design, and Insulet operates a consumable-driven recurring revenue model, as customers must continually purchase new pods. In addition to its diabetes franchise, Insulet supplies pods to Amgen for use in the Neulasta Onpro kit, a drug delivery system used to reduce infection risk following intense chemotherapy, giving the company a foothold in the broader specialty drug delivery market. The company distributes its products directly to end-users via the pharmacy channel and through independent distributors, and it is listed on NASDAQ under the ticker PODD.
- Omnipod 5 U.S. adoption accelerates automated insulin delivery growth
- GLP-1 obesity drug rise threatens type 2 insulin demand
- Drug delivery segment revenue depends on Amgen Neulasta Onpro kit
| Net Income: 302.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA 5.86 > 1.0 |
| NWC/Revenue: 35.23% < 20% (prev 81.25%; Δ -46.02% < -1%) |
| CFO/TA 0.21 > 3% & CFO 619.3m > Net Income 302.8m |
| Net Debt (472.3m) to EBITDA (575.0m): 0.82 < 3 |
| Current Ratio: 2.49 > 1.5 & < 3 |
| Outstanding Shares: last quarter (70.2m) vs 12m ago -5.27% < -2% |
| Gross Margin: 71.01% > 18% (prev 70.39%; Δ 0.62% > 0.5%) |
| Asset Turnover: 89.20% > 50% (prev 62.52%; Δ 26.68% > 0%) |
| Interest Coverage Ratio: 6.82 > 6 (EBIT TTM 473.9m / Interest Expense TTM 69.5m) |
| A: 0.34 (Total Current Assets 1.71b - Total Current Liabilities 687.5m) / Total Assets 2.99b |
| B: 0.13 (Retained Earnings 378.5m / Total Assets 2.99b) |
| C: 0.15 (EBIT TTM 473.9m / Avg Total Assets 3.25b) |
| D: 0.77 (Book Value of Equity 1.30b / Total Liabilities 1.68b) |
| Altman-Z'' = 4.45 = AA |
| DSRI: 1.03 (Receivables 544.7m/402.3m, Revenue 2.90b/2.20b) |
| GMI: 0.99 (GM 70.39% / 71.01%) |
| AQI: 1.07 (AQ_t 0.15 / AQ_t-1 0.14) |
| SGI: 1.32 (Revenue 2.90b / 2.20b) |
| TATA: -0.11 (NI 302.8m - CFO 619.3m) / TA 2.99b) |
| Beneish M = -2.75 (Cap -4..+1) = A |
As of June 23, 2026, the stock is trading at USD 138.97 with a total of 1,684,873 shares traded. Over the past week, the price has changed by -2.30%, over one month by -7.09%, over three months by -35.81% and over the past year by -52.62%.
Current recommended Stop Loss: 130.60 (which is 6% or 1.3 ATR below the current price).
Insulet has received a consensus analysts rating of 4.58. Therefore, it is recommended to buy PODD.
- StrongBuy: 17
- Buy: 4
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 242.4 | 74.4% |
P/E Trailing = 33.5327
P/E Forward = 23.0947
P/S = 3.4269
P/B = 7.6316
P/EG = 1.2664
Revenue TTM = 2.90b USD
EBIT TTM = 473.9m USD
EBITDA TTM = 575.0m USD
Long Term Debt = 929.5m USD (from longTermDebt, last quarter)
Short Term Debt = 18.6m USD (from shortTermDebt, last quarter)
Debt = 952.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 4.60m
Net Debt = 472.3m USD (calculated: Debt 952.7m - CCE 480.4m)
Enterprise Value = 10.4b USD (9.94b + Debt 952.7m - CCE 480.4m)
Interest Coverage Ratio = 6.82 (Ebit TTM 473.9m / Interest Expense TTM 69.5m)
EV/FCF = 25.26x (Enterprise Value 10.4b / FCF TTM 412.2m)
FCF Yield = 3.96% (FCF TTM 412.2m / Enterprise Value 10.4b)
FCF Margin = 14.21% (FCF TTM 412.2m / Revenue TTM 2.90b)
Net Margin = 10.44% (Net Income TTM 302.8m / Revenue TTM 2.90b)
Gross Margin = 71.01% ((Revenue TTM 2.90b - Cost of Revenue TTM 840.9m) / Revenue TTM)
Gross Margin QoQ = 69.46% (prev 72.54%)
Tobins Q-Ratio = 3.49 (Enterprise Value 10.4b / Total Assets 2.99b)
Interest Expense / Debt = 7.30% (Interest Expense 69.5m / Debt 952.7m)
Taxrate = 25.10% (101.5m / 404.4m)
NOPAT = 355.0m (EBIT 473.9m * (1 - 25.10%))
Current Ratio = 2.49 (Total Current Assets 1.71b / Total Current Liabilities 687.5m)
Debt / Equity = 0.73 (Debt 952.7m / totalStockholderEquity, last quarter 1.30b)
Debt / EBITDA = 0.82 (Net Debt 472.3m / EBITDA 575.0m)
Debt / FCF = 1.15 (Net Debt 472.3m / FCF TTM 412.2m)
Total Stockholder Equity = 1.42b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.31% (Net Income 302.8m / Total Assets 2.99b)
RoE = 21.38% (Net Income TTM 302.8m / Total Stockholder Equity 1.42b)
RoCE = 20.20% (EBIT 473.9m / Capital Employed (Equity 1.42b + L.T.Debt 929.5m))
RoIC = 16.33% (NOPAT 355.0m / Invested Capital 2.17b)
WACC = 7.50% (E(9.94b)/V(10.9b) * Re(7.69%) + D(952.7m)/V(10.9b) * Rd(7.30%) * (1-Tc(0.25)))
Discount Rate = 7.69% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -2.22 | Cagr: 0.22%
[DCF] Terminal Value 77.97% ; FCFF base≈359.0m ; Y1≈411.6m ; Y5≈605.7m
[DCF] Fair Price = 124.8 (EV 9.12b - Net Debt 472.3m = Equity 8.64b / Shares 69.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 90.49 | EPS CAGR: 54.95% | SUE: 1.29 | # QB: 1
Revenue Correlation: 99.82 | Revenue CAGR: 27.20% | SUE: 4.0 | # QB: 16
EPS current Quarter (2026-06-30): EPS=1.45 | Chg30d=+0.59% | Revisions=-4% | Analysts=20
EPS next Quarter (2026-09-30): EPS=1.64 | Chg30d=-0.01% | Revisions=-67% | Analysts=20
EPS current Year (2026-12-31): EPS=6.48 | Chg30d=+0.30% | Revisions=+77% | GrowthEPS=+30.4% | GrowthRev=+22.7%
EPS next Year (2027-12-31): EPS=8.08 | Chg30d=+0.28% | Revisions=+15% | GrowthEPS=+24.7% | GrowthRev=+18.5%
[Analyst] Revisions Ratio: +77%